ANI Pharmaceuticals, Inc.

ANIP

US00182C1036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-17 pm EDT			5-day change	1st Jan Change
62.98 ^USD	-1.95%		+0.96%	+14.22%

Jul. 15	ANI Pharmaceuticals Launches L-Glutamine Oral Powder Following FDA Approval	MT
Jul. 15	ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of L-Glutamine Oral Powder	CI

ANI Announces Launch of Paliperidone Extended-Release Tablets

January 14, 2020 at 08:30 am EST

ANI Pharmaceuticals, Inc. announced the launch of Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg. The current annual U.S. market for this product is approximately $342 million, according to IQVIA.

Latest news about ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals Launches L-Glutamine Oral Powder Following FDA Approval	Jul. 15	MT
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of L-Glutamine Oral Powder	Jul. 15	CI
ANI Pharmaceuticals Receives FDA Approval for Naproxen Delayed-Release Tablets	Jul. 02	MT
ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP	Jul. 02	CI
ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 3000E Growth Index	Jun. 30	CI
ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 3000E Index	Jun. 30	CI
ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell Microcap Index	Jun. 30	CI
ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell Microcap Growth Index	Jun. 30	CI
ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell Microcap Value Index	Jun. 30	CI
ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 3000E Value Index	Jun. 30	CI
HC Wainwright Adjusts ANI Pharmaceuticals Price Target to $94 From $87, Maintains Buy Rating	Jun. 26	MT
Top Midday Gainers	Jun. 24	MT
Sector Update: Health Care Stocks Advance Premarket Monday	Jun. 24	MT
Sector Update: Health Care	Jun. 24	MT
US Equity Futures Mixed in Premarket Action as Traders Eye Friday's Inflation Data	Jun. 24	MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Amid Uncertainty Ahead of Key Inflation Data	Jun. 24	MT
Transcript : Alimera Sciences, Inc., ANI Pharmaceuticals, Inc. - M&A Call	Jun. 24
Top Premarket Gainers	Jun. 24	MT
ANI Pharmaceuticals to Acquire Alimera Sciences in $381 Million Deal	Jun. 24	MT
ANI Pharmaceuticals, Inc. signed a definitive agreement to acquire Alimera Sciences, Inc. from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million.	Jun. 23	CI
Ani Pharmaceuticals Insider Sold Shares Worth $1,817,663, According to a Recent SEC Filing	Jun. 21	MT
Ani Pharmaceuticals Insider Sold Shares Worth $317,900, According to a Recent SEC Filing	Jun. 06	MT
ANI Pharmaceuticals Insider Sold Shares Worth $1,288,200, According to a Recent SEC Filing	Jun. 05	MT
Ani Pharmaceuticals Insider Sold Shares Worth $794,568, According to a Recent SEC Filing	May. 21	MT
ANI Pharmaceuticals Launches Kionex Suspension	May. 20	MT

Chart ANI Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.

Sector

Pharmaceuticals

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for ANI Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

64.23 USD

Average target price

83 USD

Spread / Average Target

+29.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ANI PHARMACEUTICALS, INC.	+14.22%	1.25B
ELI LILLY AND COMPANY	+55.35%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.10%	363B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+13.10%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.54%	179B
PFIZER, INC.	+4.31%	167B

Other Pharmaceuticals

ANI Pharmaceuticals, Inc.

Equities

ANIP

US00182C1036

Pharmaceuticals

ANI Announces Launch of Paliperidone Extended-Release Tablets

EPS Revisions